Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Candel Therapeutics, Inc.NASDAQ: CADL
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) turns negative
Q1 FY2026 EPS (Basic) was -$0.14, compared with $0.23 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.98.
Context
- EPS (Basic) grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 5 analysts of -$1.29 (-79.6%) for the fiscal year ending Dec 2026, a slowdown from the +58.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.14+74.1% QoQ
- Last fiscal yearDec 2025
- -$0.72+58.6% YoY
- LTMMar 2026
- -$0.98+20.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -160.9% | -155.6% | +5.3 pp |
| 1 year | +58.6% | -79.6% | -138.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (0.72) USD
- Year-over-year change
- +58.6%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.72) | +58.6% |
| FY2024 | 2024-12-31 | (1.74) | -32.8% |
| FY2023 | 2023-12-31 | (1.31) | -1217.9% |
| FY2022 | 2022-12-31 | (0.10) | +92.1% |
| FY2021 | 2021-12-31 | (1.26) | — |
EPS (Basic) vs competitors
How CADL compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +20.7% is the 5th highest of 10, against a peer median of +1.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.5 USD | -35.2% | +212.1% | |
| LTM Sep 2026 | -$0.53 USD | +55.8% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | -CN¥0.62 CNY | +85.7% | — |
GNLXGenelux Corporation | LTM Mar 2026 | -$0.88 USD | +1.1% | — |
| LTM Mar 2026 | -$0.92 USD | -29.6% | — | |
| LTM Mar 2026 | -$0.98 USD | +20.7% | — | |
| LTM Mar 2026 | -$1.1 USD | -23.6% | — | |
| LTM Mar 2026 | -$1.25 USD | -290.6% | — | |
| LTM Mar 2026 | -$1.44 USD | +23.0% | — | |
| LTM Mar 2026 | -$2.8 USD | +27.6% | — | |
| Peer median (excluding CADL) | — | +1.1% | +212.1% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 125K | 125K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 125K | 125K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 15.18M | 20.79M | 24.51M | 19.31M | 30.5M |
| Selling, General & Admin | 10.67M | 14.06M | 13.89M | 14.06M | 17.77M |
| Operating Expenses | 24.78M | 34.8M | 38.39M | 33.37M | 48.27M |
| Depreciation & Amortization | 232K | 778K | 960K | 990K | 845K |
| EBITDA | (24.42M) | (16.31M) | (34.38M) | (52.1M) | (35.22M) |
| EBITDA Margin | -19534.4% | -13046.4% | — | — | — |
| Operating Income | (24.65M) | (34.67M) | (38.39M) | (33.37M) | (48.27M) |
| Operating Margin | -19720.0% | -27739.2% | — | — | — |
| Interest Income | 0 | 1.22M | 2.08M | 1.09M | 3.92M |
| Interest Expense | 53K | 1.71M | 2.6M | 2.09M | 2.12M |
| Other Income / Expenses | (10.4M) | 15.93M | 452K | (21.81M) | 10.08M |
| Income Before Tax | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Pre-Tax Margin | -28899.2% | -15035.2% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Net Margin | -28899.2% | -15035.2% | — | — | — |
| EPS (Basic) | (1.26) | (0.10) | (1.31) | (1.74) | (0.72) |
| EPS (Diluted) | (1.26) | (0.10) | (1.31) | (1.74) | (0.72) |
| Weighted Avg Shares | 28.69M | 28.82M | 28.94M | 31.68M | 52.96M |
| Weighted Avg Shares (Diluted) | 28.69M | 28.82M | 28.94M | 31.68M | 52.96M |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.